Basel, Switzerland, May 15, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that ...
- Achieved Phase 2 primary endpoint – over 50% of patients attained Control of Disease ...
U.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant ...
